stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
Aclaris Therapeutics, Inc. (ACRS) P/E ratio
Aclaris Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| ACRS Aclaris Therapeutics, Inc. | n/m |
| APMD Apnimed, Inc. compare | 0.8× |
| VALN Valneva SE Sponsored ADR compare | 59.3× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| OBX Obsidian Therapeutics, Inc compare | — |
| IAM Iambic Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)